BEXAROTENE

Post-LOE

bexarotene

ANI Pharmaceuticals
ANDAORALCAPSULE
Approved
May 2018
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

(RXRα, RXRß, RXRγ). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the…

Pharmacologic Class:

Retinoid

Indications (2)

cutaneous manifestations of cutaneous T-cell lymphoma in patientslymphoma

Clinical Trials (5)

NCT01578499Phase 3Completed

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Started Jun 2012
131 enrolled
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
NCT01504490Phase 1Terminated

Phase I Study of CS-7017 and Bexarotene

Started Dec 2011
9 enrolled
Solid TumorsLymphomaMultiple Myeloma
NCT01134341Phase 1Completed

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Started Mar 2010
NCT00238628Phase 1/2Completed

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Started Apr 2004
12 enrolled
Lung Cancer
NCT01116622Phase 1Completed

Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract

Started Apr 2003
24 enrolled
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Company
ANI Pharmaceuticals
ANI Pharmaceuticals
BAUDETTE, MN
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers